Related Experiment Video

Updated: Jun 28, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with

Aleksandra Podlecka-Piętowska¹, Janusz Sierdziński², Monika Nojszewska³

¹Department of Neurology, Medical University of Warsaw, Warsaw, Poland. apodlecka@wum.edu.pl.

Neurologia I Neurochirurgia Polska

|January 22, 2024

Abstract

Clinical Rationale For The Study:

The rapid spread of SARS-CoV-2 throughout the world has highlighted the importance of vaccinations to control the pandemic and to protect people at risk for severe disease courses. Disease-modifying therapies (DMT) in multiple sclerosis (MS), whether immunomodulatory or immunosuppressive, may affect the immune response. Therefore, the question arose as to whether these vaccinations would be effective.

Aim Of The Study:

We planned a study to assess the immune response to SARS-CoV-2 vaccines by type of therapy.

Material And Methods:

Participants were recruited from 14 Polish MS centres. The data was obtained by neurologists using a questionnaire. We collected data on 353 MS patients (269 females, 84 males) who received complete primary SARS-CoV-2 vaccination. All persons with MS (PwMS) were treated with disease-modifying therapies.

Results:

305 out of 353 PwMS (86.4%) were positive for IgG Abs against SARS-CoV-2 S domain S1 Ag after vaccination. A strong immune response was noted in 129 PwMS (36.5%). The rate of seroconversion after SARS-CoV-2 vaccination in PwMS who received immunomodulatory DMTs (interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab) was 91.5%, in PwMS receiving immune reconstruction therapy (alemtuzumab, cladribine) was 92%, and in immunosuppressive DMTs (fingolimod, ocrelizumab), the seroconversion rate was 59%.

Conclusions And Clinical Implications:

Our study shows that, in PwMS receiving immunomodulatory therapy, the immune response to vaccination is generally excellent. Even in immunosuppressive patients, seroconversion is satisfactory.

Keywords:

COVID-19 antibodies disease-modifying therapies immune response immunosuppressive therapy multiple sclerosis vaccines

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

Related Concept Videos

Poliomyelitis

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Articles linked to this work by shared authors, journal, and citation graph.

Genetic insights into multiple sclerosis: exploring mitochondrial DNA and nuclear POLG gene variation in a Polish single-center RRMS cohort.

Neurologia i neurochirurgia polska·2026

Fruit and Vegetable, Fish, and Sugar-Sweetened Beverage Consumption Among Adults Aged 40-65 Years: A Cross-Sectional Study of Dietary Patterns and Sociodemographic Correlates in North-Eastern Poland.

Nutrients·2026

Beneficial Role of Quercetin in Prevention and Treatment of Ischemic Stroke: Mechanisms of Action and Administration Strategies.

Molecules (Basel, Switzerland)·2026

Resveratrol and Curcumin in Stroke Therapy: From Experimental Evidence to Clinical Perspectives.

Nutrients·2026

Recommendations of Multiple Sclerosis and Neuroimmunology Section of the Polish Neurological Society and the Polish Society of Gynecologists and Obstetricians for family planning and pregnancy management in women with multiple sclerosis: an update.

Neurologia i neurochirurgia polska·2026

Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis - an observational study.

Neurologia i neurochirurgia polska·2026

See all related articles